Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Krister, Wennerberg"'
Autor:
Mahesh Tambe, Sarah Unterberger, Mette C. Kriegbaum, Ida Vänttinen, Ezgi June Olgac, Markus Vähä-Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman
Publikováno v:
Cell Death and Disease, Vol 15, Iss 10, Pp 1-9 (2024)
Abstract Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges. Since no current
Externí odkaz:
https://doaj.org/article/763798c230da4af69fc6e0e76963425d
Autor:
Aleksandr Ianevski, Kristen Nader, Kyriaki Driva, Wojciech Senkowski, Daria Bulanova, Lidia Moyano-Galceran, Tanja Ruokoranta, Heikki Kuusanmäki, Nemo Ikonen, Philipp Sergeev, Markus Vähä-Koskela, Anil K. Giri, Anna Vähärautio, Mika Kontro, Kimmo Porkka, Esa Pitkänen, Caroline A. Heckman, Krister Wennerberg, Tero Aittokallio
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell
Externí odkaz:
https://doaj.org/article/ec1c01797011424aba8a717abe6ee43c
Autor:
Inès C. N. Avenel, Jesper D. Ewald, Jérémy Ariey-Bonnet, Ida H. Kristensen, Stine A. Petterson, Martin N. Thesbjerg, Mark Burton, Mads Thomassen, Krister Wennerberg, Signe R. Michaelsen, Bjarne W. Kristensen
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Glioblastoma is the most common primary brain tumor in adults, characterized by an inherent aggressivity and resistance to treatment leading to poor prognoses. While some resistance mechanisms have been elucidated, a deeper understanding of
Externí odkaz:
https://doaj.org/article/bf399aa8474f412ba51abb1b4e7f7711
Autor:
Pilar Ayuda-Durán, Johanne U. Hermansen, Mariaserena Giliberto, Yanping Yin, Robert Hanes, Sandra Gordon, Heikki Kuusanmäki, Andrea M. Brodersen, Aram N. Andersen, Kjetil Taskén, Krister Wennerberg, Jorrit M. Enserink, Sigrid S. Skånland
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell cultur
Externí odkaz:
https://doaj.org/article/0b868ee39c1047a4b864764b20e6bee8
Autor:
Oxana V. Denisova, Joni Merisaari, Riikka Huhtaniemi, Xi Qiao, Laxman Yetukuri, Mikael Jumppanen, Amanpreet Kaur, Mirva Pääkkönen, Сarina vonSchantz‐Fant, Michael Ohlmeyer, Krister Wennerberg, Otto Kauko, Raphael Koch, Tero Aittokallio, Mikko Taipale, Jukka Westermarck
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1803-1820 (2023)
Mitochondrial glycolysis and hyperactivity of the phosphatidylinositol 3‐kinase–protein kinase B (AKT) pathway are hallmarks of malignant brain tumors. However, kinase inhibitors targeting AKT (AKTi) or the glycolysis master regulator pyruvate de
Externí odkaz:
https://doaj.org/article/a2e1d31113f04fc1a661ea35069e7372
Autor:
Sarang S. Talwelkar, Mikko I. Mäyränpää, Julia Schüler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna‐Liisa Levonen, Jari Räsänen, Aija Knuuttila, Emmy W. Verschuren, Krister Wennerberg
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 747-764 (2023)
Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non‐small‐cell lung cancer (NSCLC) patients with ALK‐rearranged tumors. However, clinical resistance typically develops over time and, in the majority
Externí odkaz:
https://doaj.org/article/1563d14766b740a0a1ffecc8176e6bc3
Autor:
Oxana V. Denisova, Joni Merisaari, Amanpreet Kaur, Laxman Yetukuri, Mikael Jumppanen, Carina von Schantz-Fant, Michael Ohlmeyer, Krister Wennerberg, Tero Aittokallio, Mikko Taipale, Jukka Westermarck
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Therapeutic resistance to kinase inhibitors constitutes a major unresolved clinical challenge in cancer and especially in glioblastoma. Multi-kinase inhibitors may be used for simultaneous targeting of multiple target kinases and thereby pot
Externí odkaz:
https://doaj.org/article/222ac3f16de74dd3aae18df6f2988c8c
Autor:
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro
Publikováno v:
Haematologica, Vol 108, Iss 7 (2022)
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particular
Externí odkaz:
https://doaj.org/article/ed146fcdf2474b39baf1bf345a6c2b2c
Autor:
Sarang S. Talwelkar, Iris A.K. Lähdeniemi, Mikko I. Mäyränpää, Annabrita Hemmes, Nora Linnavirta, Jari Räsänen, Aija Knuuttila, Krister Wennerberg, Emmy W. Verschuren
Publikováno v:
STAR Protocols, Vol 3, Iss 4, Pp 101720- (2022)
Summary: Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for personalized treatment guidance due to the lengthy turnaround time. Here, we present a protocol for determining ex vivo drug sensitivities using fresh
Externí odkaz:
https://doaj.org/article/006c6459adf0456781a8ab0e155bc7a4
Autor:
Pia Roering, Arafat Siddiqui, Vanina D. Heuser, Swapnil Potdar, Piia Mikkonen, Jaana Oikkonen, Yilin Li, Sanna Pikkusaari, Krister Wennerberg, Johanna Hynninen, Seija Grenman, Kaisa Huhtinen, Annika Auranen, Olli Carpén, Katja Kaipio
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveA major challenge in the treatment of platinum-resistant high-grade serous ovarian cancer (HGSOC) is lack of effective therapies. Much of ongoing research on drug candidates relies on HGSOC cell lines that are poorly documented. The goal of
Externí odkaz:
https://doaj.org/article/682cdd5529f243d1abfe1e21b24f7510